workforce
It’s probably helping their bottom line
more than anything else.
Yes, I think so. And because it is industry
regulated, it can be subject to erosion or
strengthening more easily. But something
we are concerned about is the erosion that
can occur. This code is also under the view
of the ACCC. So they do have some say,
but they don’t intervene a great deal.
Would physical payments to any health
professional ever happen, where a
pharmaceutical company would literally
write a cheque for X amount of dollars?
I can’t really comment. It would not
surprise me, and anecdotally I have heard
that these occur. But I don’t have any data
to draw upon.
Going back to non-prescribing
clinicians. If pharmaceuticals are giving
these ‘gifts’, or helping them in these
ways, is there an ethical issue there?
It’s a complex one. We’ve got to take into
account the fact that nurses can really
benefit the pharmaceutical industry – and
this is a good thing, because they make
our medicines. It’s good to have a nurse,
say, on the advisory committee, or giving
insights to the pharmaceutical industry on
the medicines that patients are using or
how they’re dealing with it, and so forth.
But we can’t overlook the fact there
is a danger as well, that these payments
would subconsciously or otherwise
influence the sort of practice of the nurse
who is receiving them. Or they could
influence their colleagues to bias their
clinical care in a way that benefits the
pharmaceutical company.
We have to remember that a lot of what
the company is doing is marketing strategy.
And we can see that, with doctors, it’s
highly effective. characteristics of the highest paid people
that those companies are sponsoring.
It stands to reason that if you influence
a doctor, they will more likely prescribe
this medication. But how does a non-
prescribing nurse influence a doctor? In Australia we have quite good records,
although they’re not very accessible.
I think we could improve our capture.
So, for example, we only capture 35
pharmaceutical companies out of all the
companies in Australia. We don’t capture
medical device companies, which we
know are doing a lot of marketing.
In the scheme of the world, we’re doing
quite well because we’re capturing these
non-prescribing healthcare professionals,
which most aren’t. However, we aren’t
capturing a lot of the types of exposure to
Something interesting coming out of
the data are the areas being targeted in
terms of the non-prescribing healthcare
professionals. We’re seeing people targeted
with roles in chronic disease and areas that
may require high adherence to medicines.
These are areas in which nurses are
encouraged to play quite a big role.
Nurses often have roles on formulary
committees. They can influence or
recommend things the prescriber might
use, and they also become very close, I
suppose, to the patient. They are a highly
trusted source that can influence the sorts
of medicines the patient might want. So
I think nurses and other non-prescribers
can really influence multiple points of the
chain, from purchasing the product, to
influencing the prescriber, to influencing
the patient.
I’m not using ‘influencing’ in a bad way
there. But they have, I think, a lot more
influence than we sometimes give them
credit for.
What were the methods you used to
find and make sense of this data?
We got publicly available reports from
Medicines Australia. Thirty-five large
pharmaceutical companies who are
members of that organisation submit
reports to them every six months. This is
where we obtained the data.
We then tried to identify unique people.
Sometimes that was a bit challenging,
because their names might be presented
differently and so forth. Then we did a
descriptive analysis using what was in that
data to pull out the types of payments that
people are getting, the types of companies
that are sponsoring non-prescribers, how
much different people might be getting.
Then we also did a little bit of a dig,
almost like taking some case studies and
looking at which of the companies are
paying the most to these non-prescribing
healthcare professionals, and what are the
Did you have any engagement with any
of these healthcare professionals?
No, we didn’t contact anyone.
Do you feel there needs to be more
transparency on who’s being paid what
in the healthcare profession?
Nurses can influence
multiple points of the
chain, from purchasing the
product, to influencing the
prescriber and the patient.
industry that people get. These payments
are really a very small part of exposure
to industry.
Do you see your study having an effect
on the way non-prescribing clinicians
will accept payments?
I think that, more than necessarily
having an effect on whether individuals
accept payments – although that
would be beneficial – what I really like
about our study is that it shows that the
pharmaceutical industry isn’t ignoring
non‑prescribing healthcare professionals.
We’ve been a bit dismissive, I think,
of their importance. There’s therefore
an idea that payments or any kind of
pharmaceutical industry interaction with
non-prescribing healthcare professionals
is sort of irrelevant.
Our study shows the industry doesn’t
think it’s irrelevant. Perhaps we need to
think about whether our non-prescribing
or non-medical, non-doctor healthcare
professionals are well equipped to evaluate,
understand the risks of, and know how to
deal with the industry interactions they
face day to day. ■
nursingreview.com.au | 29